PRESS RELEASE published on 03/14/2025 at 17:45, 1 year 4 months ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics lance un processus de recherche de repreneurs dans le cadre de son redressement judiciaire. Appel d'offres ouvert jusqu'au 11 avril 2025 Appel D'offres Redressement Judiciaire Repreneurs Procédure PHAXIAM Therapeutics
BRIEF published on 03/06/2025 at 18:01, 1 year 4 months ago PHAXIAM Therapeutics entre en redressement judiciaire et retarde ses résultats financiers Retard Des Résultats Financiers Administrateur Judiciaire Suspension Des Échanges Mise Sous Séquestre De PHAXIAM Défis Biotechnologiques
BRIEF published on 03/06/2025 at 18:01, 1 year 4 months ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 4 months ago Informations privilégiées / Autres communiqués PHAXIAM annonce l'ouverture d'une procédure de redressement judiciaire et le report de la publication de ses résultats financiers 2024. La Société se place sous la protection du Tribunal de commerce de Lyon Résultats Financiers Tribunal De Commerce Redressement Judiciaire PHAXIAM Procédure
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 4 months ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year 4 months ago Suspension de la Cotation de PHAXIAM Therapeutics Euronext Paris Biopharmaceutique Suspension Cotation PHAXIAM Therapeutics Infections Résistantes
BRIEF published on 03/06/2025 at 11:45, 1 year 4 months ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
PRESS RELEASE published on 03/06/2025 at 11:40, 1 year 4 months ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics suspend sa cotation sur Euronext Paris en attendant un prochain communiqué. La société développe des traitements innovants contre les infections bactériennes Cotation Suspension Traitements Innovants PHAXIAM Therapeutics Infections Bactériennes
BRIEF published on 12/30/2024 at 17:50, 1 year 6 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
BRIEF published on 12/30/2024 at 17:50, 1 year 6 months ago PHAXIAM Therapeutics : résultats prometteurs de l’étude pilote PhagoDAIR PHAXIAM Therapeutics Étude PhagoDAIR Phages Anti-S. Aureus Phase II GLORIA Contrôle De L'infection
Published on 07/17/2026 at 15:00, 22 hours 21 minutes ago Four Nines Gold to Showcase Hayden Hill Opportunity to U.S. Investors at OTC Markets Virtual Investor Conference
Published on 07/17/2026 at 14:00, 23 hours 21 minutes ago Redwood AI Announces Pricing of $3.5 Million Private Placement
Published on 07/17/2026 at 13:00, 1 day ago Blue Lagoon Surpasses $10 Million In Revenue As Dome Mountain Production Rises To 125 Tonnes Per Day
Published on 07/17/2026 at 01:00, 1 day 12 hours ago RJK Explorations Ltd. Announces Closing of Private Placement for Gross Proceeds of $310,000
Published on 07/17/2026 at 00:00, 1 day 13 hours ago LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
Published on 07/18/2026 at 08:00, 5 hours 21 minutes ago Northern Data AG – Changes to the Supervisory Board and the Management Board
Published on 07/17/2026 at 20:35, 16 hours 46 minutes ago Farizon Opens Global Spare Part Distribution Center to Strengthen International Aftersales Support
Published on 07/17/2026 at 18:55, 18 hours 26 minutes ago CGTN: China vows to make AI a driver for shared prosperity amid widening AI divide
Published on 07/17/2026 at 18:32, 18 hours 49 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/17/2026 at 18:31, 18 hours 50 minutes ago Déclaration hebdomadaire d'opérations effectuées du 13 au 17 juillet 2026
Published on 07/17/2026 at 18:31, 18 hours 50 minutes ago Disclosure of transactions in own shares from July 13 to July 17, 2026
Published on 07/17/2026 at 18:00, 19 hours 21 minutes ago Information regarding compliance with gender balance rules within the Board of Directors
Published on 07/17/2026 at 18:00, 19 hours 21 minutes ago Informations relatives au respect des règles de représentation équilibrée au sein du Conseil d’administration
Published on 07/17/2026 at 17:45, 19 hours 36 minutes ago Imerys-07-2026-information-share-capital-and-voting-rights-as-of-30-June-2026
